Related Experiment Video
Updated: May 23, 2026
07:25
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Castration-resistant prostate cancer: systemic therapy in 2012.
Fernando C Maluf1, Oren Smaletz, Daniel Herchenhorn
1Serviço de Oncologia Clínica, Hospital São José, Beneficência Portuguesa de São Paulo, São Paulo, SP, Brazil. maluffc@uol.com.br
Clinics (Sao Paulo, Brazil)
|April 24, 2012
Summary
Prostate cancer management has evolved, with new therapies like docetaxel and cabazitaxel improving outcomes for castration-resistant prostate cancer. Early diagnosis and improved communication are key for effective patient care.
Area of Science:
- Oncology
- Urology
Background:
- Prostate cancer is a prevalent male neoplasm, often diagnosed early with an indolent course.
- While localized disease is curable, metastatic progression and androgen resistance pose significant challenges.
- Castration-resistant prostate cancer (CRPC) requires specialized care and improved oncologic communication.
Purpose of the Study:
- To review current therapeutic strategies for castration-resistant prostate cancer.
- To highlight advancements in chemotherapy and novel agents for advanced prostate cancer.
- To emphasize the importance of multidisciplinary care in managing CRPC.
Main Methods:
- Review of clinical trials and established treatment protocols for prostate cancer.
- Analysis of chemotherapy agents, including docetaxel and cabazitaxel, in CRPC management.
- Discussion of emerging therapies and their impact on patient survival.
Main Results:
- Docetaxel is the standard first-line chemotherapy for CRPC.
- Cabazitaxel demonstrated improved overall survival as a second-line therapy compared to mitoxantrone in docetaxel-pretreated patients.
- Other agents like abiraterone and sipuleucel-T are utilized, with ongoing research for novel treatments.
Conclusions:
- Significant progress has been made in treating castration-resistant prostate cancer.
- Chemotherapy, particularly docetaxel and cabazitaxel, plays a crucial role in prolonging survival.
- Continued investigation into novel therapies is essential to further improve outcomes for advanced prostate cancer patients.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...